Fusion Antibodies Share Discussion Threads

[superg1] 20/9/2020 20:31

Diversification

They have proven up the Antigens therefore they had the antibody generation recipe before the test results. So naturally the antibody generation will follow.

[diversification] 20/9/2020 20:10

Very true Phil, you would like to think that both new, existing and future shareholders have done some research on this and are keeping quite going into tomorrow so that they can position accordingly.

My gut feeling is that this will open up 30/40% on Monday morning. I could be accused of ramping, but a market cap of anything less than 200m prior to the antibody neutralizing news (which will happen) is still to low given the performance of its peer, Twist which has set a benchmark. £1.6b increase in market cap.

It would be nice to hear from the company via interview Monday, I will he asking the question. They might be able to present a clearer time frame on therapeutic news and forward plans with partnering discussions.

[phil1969] 20/9/2020 18:54

What I find most encouraging is despite a 150% spike and eventual 90% gain on Friday, non of the usual suspects have appeared on ADVFN or LSE message boards over the weekend.FAB is the real deal, especially when compared to most of the big movers in this casino. I'm in until £200m mcap reached.

[superg1] 20/9/2020 18:42

20pc

Fusion clearly have a carry in trials I think the CEO said some in phase 2 but they haven’t said what or where.

A bit of digging may identify some of them.

[20pc] 20/9/2020 14:53

I was wondering why FAB released their RNS at 9:30 on Thursday.

Hoping that FAB had been working with Roche and agreed to announce after Roche released their news on Thursday re Roche launches new quantitative antibody test … Which uses similar phrases to FAB.

Thought it likely that FAB had worked with Roche in the past and confirmed here

[...]

“Some of the drugs it has worked on are going through phase I and II human trials, while another that Fusion contributed to has been patented by Swiss giant Roche.

If it is the case then are the tests, using FAB antigens, already available from last Thursday.

Roche link.



Any views appreciated.

[diversification] 20/9/2020 13:18

In my view the market cap of twist v Fab makes FaB vulnerable to a takeover. These companies seem to thrive and pride themselves on their libraries to gain a competitive edge. Well if FAB truly has a market leading platform, it’s value is well in excess of what the market values it at today, and Friday’s RNS has proven its validity.

[diversification] 20/9/2020 12:26

Twist bioscience Corp has seen its market cap increase by $2b since the intention/ introduction of neutralizing antibodies.

You can see the shear potential of FAB given its very low market cap.

Wow.

[superg1] 20/9/2020 12:02

The biggest earning drugs now have antibody inclusion, Scancell had some great results re cancer. That's just and example of use, not a tip.

The biggest drug revenue earner uses such tech, as the CEO said it's returning $20 billion in revenue a year for those involved.


I though the £150m estimate for a full lifetime carry to Fusion on one drug sounded a bit steep but it doesn't sound mad at all on the billions per year revenue each drug to full market can create.

Fusion do have some varies out there but in what trials I have no idea, some are phase 2 as I recall from one interview

[superg1] 20/9/2020 11:57

On the 100% correlation comment

These antigens have been tested by external partners against patient blood samples and show a 100% correlation


Antigens are the catalyst for the body to make antibodies.

So I take it imo to mean the antigens FAB have, develop the relevant antibodies in all testing done IE 100%.

So they have identified and engineered the right antigens to develop the antibodies which no doubt has been progressing too and will also become news.

The FAB technology is clearly highly regarded by big Pharma and bio companies. No doubt they will be after the antigens as in the news which are now on offer.

The terms they use in short mean FAB has the suite of options for big pharmas.

The option to produce accurate tests, the option to produce vaccines and the exciting one, antibodies to neutralise Covid via an injection.

A mass of covid killing antibodies to neutralise Covid before it takes hold.

Covid is just the add on though, they have 100s in the library.

[phil1969] 20/9/2020 11:52

I suppose what everyone needs to know for Monday morning is as well as FAB being an excellent business, in very good financial shape, has an extensive diversified pipeline and steady revenue stream which has the potential to grow, especially with the CV antibodies they are working on.

How does this affect potential investors after a 90% price increase on Friday.

It’s all in the mcap and FABs mcap is under £50m and 60% of the shares are in directors or funds hands.

This is a £250m business if it’s peers are to be compared and a rerate is on the cards now it’s on so many more radars after fridays RNS

£10 a share is where it should be trading while CV is a factor.

Holding long and hard for a more realistic mcap.

[superg1] 20/9/2020 11:49

So the fund raise was 28th April to expand the equipment and staff they needed to rapidly work on Covid and add it to their offering.

6th July

The Company has commenced its proof-of-concept work on the Mammalian Antibody Library Discovery Platform (the "Library") and hit its first milestone in the COVID-19 associated project, with the synthesis of the antibody library DNA.

The Company has also made rapid progress on the design, expression and validation of the COVID-19 antigens and now has sufficient quantities of two variants to be used in the panning of the library for specific antibody producing cells, which is the next phase of the Library development programme

we have made excellent progress on the launch of the proof-of-concept for the Mammalian Library and have generated a panel of SARS-CoV-2 S antigens.

The new last week

The Company's proof-of-concept work on the Mammalian Antibody Library Discovery Platform (the "Library") continues to progress according to plan. The Company has made progress on the design, expression and validation of SARS-CoV-2 proteins, commonly known as Coronavirus spike proteins. These antigens have been tested by external partners against patient blood samples and show a 100% correlation with results from a leading certified benchmark test.

The Company is now offering these antigens on a commercial basis to companies and researchers worldwide. Unlike the PCR tests that are currently being used to identify the presence of COVID-19, Fusion's antigens are able to confirm recent past infections and determine levels of neutralising antibodies to COVID-19. This could be invaluable for disease modelling and public health policy, as it will assist in the determination of true transmission rates and case fatality rates.

[superg1] 20/9/2020 11:42

A different interview to the proactive investors one where he states the plan is to produce antibodies for Covid to inject and neutralise the virus in people.

That in short takes way the 2 week waiting time for the body to generate its own by which time the virus has multiplied exponentially and in many cases caused serious issues and death.

They have an extensive library of other antibodies

He also mentioned that the library will allow customers to vet to their end desired selection of antibody use 8 times more quickly than the typical animal testing route.

I would imagine that amounts to years and receives the controversial testing part for those available in the library.

[superg1] 20/9/2020 11:21

The note mentions 8 of 10 of the top pharmas.

That too is in the admission document and was mentioned by the CEO in the May interview

'The Company has an international, blue-chip client base, which includes eight of the top ten global pharmaceutical companies by revenue.'

But it also says

as well as many of the top ten biotech and diagnostic companies by revenue.

So Fusion are well known for their expertise in this sector.

[superg1] 20/9/2020 11:16

There is also a comment about the carry into drugs in trials in the note having no details but estimating a lifetime payment of £150m for a drug successfully entering the market.

Those comments can be directly linked to the admission document

Admission document

the Company has completed a number of projects for clients which include payments to the Company on the achievement by the client of certain milestones. The Board believes the Company can increase profitability by including milestone payments as a standard provision in its customer contracts where possible. Where the milestones are achieved, this would generate further revenue for the Company without any additional development expenditure by the Company.

Since 1 January 2012, the Company has worked on over 100 antibody humanisation projects, of which eight contain milestone payment terms. The Board anticipates that a number of these projects will enter clinical trials over the three-year period following Admission.

That is from 2017.

[gimmetheloot] 20/9/2020 11:12

Data is the new gold and you can see why the big pharma companies are in close collaboration with FAB

[superg1] 20/9/2020 11:07

Yeah Great read

In particular the bit about the library of antibodies which I didn't realise removes the needs for animal testing if the desired recipe is already in the library.

One the revenue front I see the expected revenue for the last year was £3, as in write top which I assume was taken form the forecast note.

Full year revenues increased by 79% to GBP3.9m (2019: GBP2.2m)

That's 30% higher than the forecast.

A part not really explained, although it can be deduced is the fact FAB are not big spenders like you would expect from a Bio because of their service provider nature.

But as explained they do have the big revenue potential and in a much wider range of drugs than your typical go it alone bio type company.

EG IPO 2017 and as said the £3m raise was the first one since IPO.

[gimmetheloot] 20/9/2020 11:02

Woah this MAL looks like a big game changer

[prince7652] 20/9/2020 09:28

Acuere Great read Thanks

[superg1] 20/9/2020 09:16

Acuere

Thanks for the link I was unaware. Mid reading and it's a brilliant read to understand FAB. It will certainly save me a load of time.

Off now to read part 1 and part 2 in full.

[acuere] 20/9/2020 08:12

Worth repeating the link to this must read.



And remember to click on the link to the first part of the research.

[blueball] 20/9/2020 07:55

stay long.

[phil1969] 19/9/2020 22:50

Great work superg. If I find anything new I'll will add but you seem to be posting all the important info.

[superg1] 19/9/2020 19:45

From this list

Lilly/Abcellera
Regeneron
Lilly/Junshi
Celltrion
Sab Biotherapeutics
Glaxosmithkline/Vir
Astrazeneca
Sorrento
Brill Bio
Yumab
Molecular Partners
Systimmune
Xencor/Vir
Atreca/Beigene/IGM
Amgen/Adaptive
Ossianix
Sorrento
Sorrento/Mabpharm
Fusion Antibodies
Fusion Antibodies
Virna